InVitae Corp (NYSE:NVTA) – Investment analysts at Leerink Swann issued their Q1 2019 earnings estimates for shares of InVitae in a note issued to investors on Tuesday. Leerink Swann analyst P. Souda forecasts that the medical research company will post earnings per share of ($0.41) for the quarter. Leerink Swann currently has a “Outperform” rating and a $10.00 target price on the stock. Leerink Swann also issued estimates for InVitae’s Q2 2019 earnings at ($0.38) EPS, Q3 2019 earnings at ($0.33) EPS and Q4 2019 earnings at ($0.21) EPS.

NVTA has been the topic of a number of other research reports. BidaskClub lowered InVitae from a “buy” rating to a “hold” rating in a research report on Thursday, October 26th. Zacks Investment Research lowered InVitae from a “hold” rating to a “sell” rating in a research report on Thursday, January 4th. Benchmark dropped their price target on InVitae from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Ladenburg Thalmann Financial Services began coverage on InVitae in a research report on Friday, January 5th. They set a “buy” rating and a $15.00 price target on the stock. Three research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. InVitae currently has a consensus rating of “Hold” and a consensus price target of $12.40.

InVitae (NYSE NVTA) traded up $0.26 during midday trading on Wednesday, hitting $7.03. The stock had a trading volume of 1,440,000 shares, compared to its average volume of 563,195. The firm has a market capitalization of $372.21 and a price-to-earnings ratio of -2.76. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.61 and a current ratio of 2.61. InVitae has a 52 week low of $6.64 and a 52 week high of $11.88.

InVitae (NYSE:NVTA) last released its quarterly earnings results on Monday, November 6th. The medical research company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.02). InVitae had a negative return on equity of 115.25% and a negative net margin of 206.95%.

Institutional investors have recently made changes to their positions in the stock. State Street Corp raised its position in InVitae by 43.1% in the 2nd quarter. State Street Corp now owns 577,978 shares of the medical research company’s stock valued at $5,528,000 after buying an additional 174,016 shares during the last quarter. Northern Trust Corp raised its position in InVitae by 39.0% in the 2nd quarter. Northern Trust Corp now owns 433,113 shares of the medical research company’s stock valued at $4,140,000 after buying an additional 121,409 shares during the last quarter. Allianz Asset Management GmbH raised its position in InVitae by 110.6% in the 3rd quarter. Allianz Asset Management GmbH now owns 168,856 shares of the medical research company’s stock valued at $1,582,000 after buying an additional 88,674 shares during the last quarter. Goldman Sachs Group Inc. raised its position in InVitae by 165.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 54,906 shares of the medical research company’s stock valued at $525,000 after buying an additional 34,218 shares during the last quarter. Finally, Orbimed Advisors LLC raised its position in InVitae by 232.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,518,197 shares of the medical research company’s stock valued at $14,226,000 after buying an additional 1,061,531 shares during the last quarter. 64.67% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/leerink-swann-weighs-in-on-invitae-corps-q1-2019-earnings-nvta/1812759.html.

InVitae Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Earnings History and Estimates for InVitae (NYSE:NVTA)

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.